Mangalam Drugs and Organics share news and announcements
NSE: MANGALAMBSE: 532637Pharmaceuticals & BiotechnologySmall Cap
Last close ₹28.65down ₹0.92 (3.11%)BSE ₹28.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹29.57.
52-week range of traded prices to 23 Oct 2026
₹22.80Low, 29 Dec 2025₹71.99High, 23 Oct 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹45 Cr3,423rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 14 May 2026
- 0.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- −30.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- −12.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 14 May 2026
- 1.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 19,55176.4% delivered
Mangalam Drugs and Organics share news and announcements
527 announcements, routine notices left out, newest first. Page 6 of 11.
Dec 2020
Nov 2020
26 Nov · Related Party Transactions
12 Nov · Board meeting
Sep 2020
14 Sep · Legal
Exchange has sought clarification from Mangalam Drugs And Organics Limited for the quarter ended 30-Jun-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
Aug 2020
14 Aug · Legal
Exchange has sought clarification from Mangalam Drugs And Organics Limited with respect to announcement dated 10-Aug-2020, regarding appointment of C.S. Ajgaonkar & Co. - Chartered Accountants as Internal Auditors of the Company. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment). The response of the Company is awaited.10 Aug · Board meeting
Jul 2020
16 Jul · Related Party Transactions
Jun 2020
29 Jun · Board meeting
11 Jun · Updates
May 2020
Mar 2020
Jan 2020
24 Jan · Board meeting
Dec 2019
Nov 2019
21 Nov · Legal
Exchange has sought clarification from Mangalam Drugs And Organics Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.14 Nov · Related Party Transactions
Oct 2019
Sep 2019
Aug 2019
Jul 2019
26 Jul · Board meeting